US 12,137,723 B2
Oral products with active ingredient combinations
Anthony Richard Gerardi, Winston-Salem, NC (US); Ross Jay Oden, Winston-Salem, NC (US); Matthew Evan Lampe, Winston-Salem, NC (US); Kristen Ann Spielbauer, Kernersville, NC (US); and Michael Andrew Zawadzki, Durham, NC (US)
Assigned to NICOVENTURES TRADING LIMITED, London (GB)
Filed by NICOVENTURES TRADING LIMITED, London (GB)
Filed on Mar. 1, 2021, as Appl. No. 17/187,987.
Application 17/187,987 is a continuation of application No. PCT/IB2020/061472, filed on Dec. 4, 2020.
Application PCT/IB2020/061472 is a continuation in part of application No. 16/706,974, filed on Dec. 9, 2019.
Claims priority of provisional application 63/036,254, filed on Jun. 8, 2020.
Prior Publication US 2021/0177038 A1, Jun. 17, 2021
Int. Cl. A24B 13/00 (2006.01); A24B 15/30 (2006.01); A24B 15/32 (2006.01); A24B 15/38 (2006.01); A24B 15/42 (2006.01)
CPC A24B 13/00 (2013.01) [A24B 15/301 (2013.01); A24B 15/303 (2013.01); A24B 15/306 (2013.01); A24B 15/308 (2013.01); A24B 15/32 (2013.01); A24B 15/385 (2013.01); A24B 15/42 (2013.01)] 25 Claims
 
1. A composition in meltable form, configured for oral use, the composition comprising:
at least one active ingredient comprising caffeine and theanine, caffeine and taurine, or caffeine, theanine, and taurine;
a sugar alcohol; and
a lipid;
wherein the meltable form comprises the composition as a homogenous mixture.